Vitamin A Ophthalmic Composition Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ophthalmic compositions containing high concentrations of vitamin A face stability challenges due to vitamin A's instability in aqueous solutions, which is not adequately addressed by previous stabilization methods.
Innovation Solution
Formulating an ophthalmic composition with at least 0.4 W/V % of polyoxyethylene polyoxypropylene glycol and trometamol, along with vitamin A, to enhance the stability of vitamin A, even at concentrations of 50,000 units/100 mL or higher.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If vitamin A is formulated at high concentration (≥50,000 units/100 mL) in aqueous ophthalmic composition, then therapeutic effectiveness is improved, but stability deteriorates due to oxidation and degradation
Solution Approach 1:
The patent introduces polyoxyethylene polyoxypropylene glycol as an intermediary substance that forms a protective complex with vitamin A, shielding it from oxidative degradation. This nonionic surfactant acts as a mediator between vitamin A and the aqueous environment, preventing direct contact with oxygen and other degrading factors while maintaining high vitamin A concentration in the formulation.
Solution Approach 2:
The patent creates a composite stabilization system combining multiple components: polyoxyethylene polyoxypropylene glycol as the primary stabilizer, additional antioxidants (vitamin E, dibutylhydroxytoluene) as secondary protectors, and trometamol as a pH buffer. This multi-component composite approach provides synergistic protection against various degradation pathways including oxidation, hydrolysis, and pH-dependent degradation.
2Stability of the object's composition
If conventional stabilization methods (nonionic surfactants, vitamin E) are used, then some stability is improved, but stability at high concentration (≥50,000 units/100 mL) remains insufficient
Solution Approach 1:
The patent optimizes specific formulation parameters including the concentration of polyoxyethylene polyoxypropylene glycol (0.01-5% w/v), pH range (5.0-8.0 using trometamol buffer), and ratios of stabilizing components. By carefully controlling these parameters, the formulation achieves enhanced stability that allows vitamin A to be maintained at high concentrations without excessive degradation, overcoming the limitations of conventional stabilization methods.
3Quantity of substance
If high concentration of vitamin A is formulated, then therapeutic effect for corneal and conjunctival disorders is enhanced, but eye irritation increases
Solution Approach 1:
The polyoxyethylene polyoxypropylene glycol serves as a protective intermediary that solubilizes high concentrations of vitamin A in the aqueous formulation, preventing direct contact between the lipophilic vitamin and ocular tissues. This mediator reduces irritation while maintaining therapeutic efficacy by controlling the release and distribution of vitamin A in the eye.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively stabilizes vitamin A, providing improved storage stability and reducing eye irritation, while maintaining its therapeutic effects for corneal and conjunctival disorders and dry eye treatment.
Implementation Method 1
when at least 0.4 W/V % of polyoxyethylene polyoxypropylene glycol and trometamol are formulated in an ophthalmic composition containing at least 50,000 units/100 mL of vitamin A, the stability of vitamin A can be significantly enhanced
Implementation Method 2
vitamin A that is a lipophilic vitamin is very sensitive to air, light, heat, acids, metal ions and the like
Data Source
AI summary
Disclosed is an ophthalmic composition containing (A) not less than 50,000 units/100 mL of vitamin A, (B) not less than 0.4 W/V % of a polyoxyethylene polyoxypropylene glycol, and (C) trometamol.